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Abstract 
Background: Effective brief treatments for methamphetamine use disorders (MAUD) are urgently needed to com-
plement longer more intensive treatments in low and middle income countries, including South Africa. To address 
this gap, the purpose of this randomised feasibility trial was to determine the feasibility of delivering a six-session 
blended imaginal desensitisation, plus motivational interviewing (IDMI) intervention for adults with a MAUD.
Methods: We enrolled 60 adults with a MAUD and randomly assigned them 1:1 to the IDMI intervention delivered by 
clinical psychologists and a control group who we referred to usual care. Feasibility measures, such as rates of recruit-
ment, consent to participate in the trial and retention, were calculated. Follow-up interviews were conducted at 
6 weeks and 3 months post-enrollment.
Results: Over 9 months, 278 potential particiants initiated contact. Following initial screening 78 (28%) met inclusion 
criteria, and 60 (77%) were randomised. Thirteen of the 30 participants assigned to the treatment group completed 
the intervention. Both psychologists were highly adherent to the intervention, obtaining a fidelity rating of 91%. In 
total, 39 (65%) participants completed the 6-week follow-up and 40 (67%) completed the 3-month follow-up. The 
intervention shows potential effectiveness in the intention-to-treat analysis where frequency of methamphetamine 
use was significantly lower in the treatment than in the control group at both the 6 week and 3-month endpoints. No 
adverse outcomes were reported.
Conclusions: This feasibility trial suggests that the locally adapted IDMI intervention is an acceptable and safe inter-
vention as a brief treatment for MAUD in South Africa. Modifications to the study design should be considered in a 
fully powered, definitive controlled trial to assess this potentially effective intervention.
Trial registration The trial is registered with the Pan African Clinical Trials Registry (Trial ID: PACTR201310000589295)
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Background
Substance use disorders represent a major public health 
problem, both globally and in South Africa. Substance 
use contributes significantly to the global burden of 
disease, accounting for 11% of total health burden [1]. 
Similar to other low and middle income countries, data 
from a nationally representative community sample in 
South Africa indicate a high lifetime prevalence (13.3%) 
and early onset (21 years) of substance use disorders [2]. 
In the Western Cape Province, the primary substance of 
abuse is alcohol, but recent years have seen increases in 
the use of methamphetamine (MA) [3] which is now the 
third most commonly used substance (after alcohol and 
cannabis) among people seeking substance use treatment 
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in the Western Cape. Although nationally representa-
tive prevalence data on MA use does not exist, a study 
investigating drug and human immunodeficiency virus 
(HIV) risk behaviour in 1379 South Africans from three 
communities reported that 7.3% of those interviewed had 
used MA more than once [4].
MA use is associated with several negative sequelae. 
These include a range of psychiatric symptoms such as 
depression and suicide, as well as serious medical condi-
tions such as cardiac arrhythmias and myocardial infarc-
tion [5–8]. In addition, MA use has been associated with 
neurocognitive impairment, interpersonal violence and 
risk of HIV acquisition and transmission [9, 10], two key 
drivers of South Africa’s burden of disease.
Given the psychological and public health implications 
associated with MA use, researchers from high-income 
countries have investigated the efficacy of a variety of 
psychological treatments for MA use [11]. Contingency 
management, interpersonal therapy, cognitive behav-
ioural therapy (CBT) (including the Matrix Model), and 
motivational approaches, such as motivational interview-
ing, have shown to reduce MA use [11–14]. Despite the 
availability of effective treatments, many people globally 
with a methamphetamine use disorder (MAUD), do not 
receive adequate treatment [15].
This is also true for South Africa, where community-
based studies have found that although people who use 
MA would generally meet diagnostic criteria for a severe 
substance use disorder and recognise the need to get 
treatment [16, 17], less than 3% of MA users who need 
treatment ever access these services [16, 17] due to a 
variety of structural barriers [18, 19]. A particularly sali-
ent barrier is the limited allocation of funding resulting 
in many non-for profit facilities being unable to con-
tinue to provide free services to clients from vulnerable 
communities [16]. Further, the existing substance abuse 
treatment system in South Africa relies heavily on the 
provision of high threshold, drug “rehabilitation” services 
offered by specialised service providers. For example, in 
the Western Cape Province, the Matrix Model is offered 
at various outpatient services and consists of a 16-week 
treatment programme that incorporates elements from 
motivational interviewing, cognitive behavioural treat-
ment and contingency management through individual, 
group, and family sessions [20, 21]. While this is a pro-
gramme of known efficacy, the programme’s coverage is 
not sufficient to meet population needs for this service, 
particularly among disadvantaged communities [18]. In 
addition, the programme is very long and attrition rates 
are high [22]. To address this treatment gap and respond 
to the MA epidemic, briefer efficacious MA treatments 
are needed to complement the high threshold services 
that are available.
One brief treatment with potential for use in South 
Africa to treat MAUD is a manualized programme that 
includes components of cognitive-behavioural therapy, 
motivational interviewing, and imaginal exposure devel-
oped by Grant et  al. [23]. Imaginal desensitisation plus 
motivational interviewing (IDMI) is a structured, six-
session brief treatment with evidence of effectiveness for 
the treatment of impulse control disorders in the United 
States [24], and has been adapted for the treatment of 
pathological gambling in South Africa [25]. This treat-
ment approach may be helpful for MAUD given that 
many of the mechanisms underlying behavioural addic-
tions (such as pathological gambling) and substance use 
disorders are shared [26]. However, unanswered ques-
tions about the feasibility of implementing this treatment, 
it’s acceptability and potential efficacy for addressing 
MAUD among South African populations needed to be 
addressed before recommendations about its use can be 
made.
Trial objectives
The primary objectives of this study were to (i) examine 
the feasibility of a six-session brief IDMI treatment for 
South Africans with MAUD as well as; (ii) the feasibility 
of study procedures including the performance of pri-
mary and secondary outcome measures to inform a fully 
powered trial. A second objective was to explore the ini-
tial effect of this IDMI intervention on MA use.
Methods
This paper has been written in accordance with the Con-
solidated Standards of Reporting Trials (CONSORT) 
2010 statement: extension to randomised pilot and feasi-
bility trials [27] and the Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) checklist 
[28].
Participants
Sixty participants were recruited through several avenues 
including referral from health care services, local non-
government organisations (NGOs) and advertisements in 
local newspapers. Eligible participants were between 18 
and 65  years of age; had at least a grade 9 education (a 
proxy for English literacy), met Diagnostic and Statistical 
Manual fourth edition (DSM-IV) criteria for MA abuse 
or dependence according to the Mini-International Psy-
chiatric Interview (MINI) substance use module, and 
self-reported MA as their drug of choice. Patients with 
other co-occurring substance use disorders were not 
excluded. Exclusion criteria included participants meet-
ing criteria for bipolar disorder, suicidality, schizophrenia 
(including psychosis) and antisocial personality disorder 
(as assessed through the MINI).
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Procedure
See Fig.  1 for consort diagram. Interested participants 
contacted the study’s research assistant by phone or text 
message. A pre-screener was then administered over the 
phone. Questions pertaining to the age of the participant 
and frequency of drug use were elicited. All those not 
excluded from the pre-screener were asked to attend a 
screening assessment at Groote Schuur Hospital in Cape 
Town. During this assessment, all participants received a 
psychiatric assessment by a Registered Counsellor, with a 
4-year honours degree in Psychology. Psychiatric diagno-
ses were obtained using the MINI. All participants that 
were excluded due to a dual diagnosis (bipolar disorder, 
schizophrenia and antisocial personality disorder) were 
referred to a dual diagnosis clinic located at the hospital 
for further assessment and treatment.
All participants who met criteria and consented to par-
ticipate in the study completed an interviewer-adminis-
tered baseline questionnaire on self-reported substance 
use and mental and physical health. They were then ran-
domly assigned to the IDMI treatment or control group 
(1:1). The treatment group received the six-session treat-
ment, while the control group were referred to local sub-
stance use treatment centres for treatment.
Follow-up interviews were conducted at 6  weeks and 
3  months following study enrolment, at which time 
the baseline questionnaire was re-administered. Gro-
cery vouchers of R50 (approximately $5) were given to 
Fig. 1 Consort diagram for feasibility study
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participants at each research assessment. To limit attri-
tion, telephone and text message reminders were sent to 
participants. Participants were also compensated for any 
travel expenses.
Randomisation and blinding
Participants were randomly allocated in a 1:1 ratio to 
either the intervention or comparison arm. The ran-
domisation sequence was prepared by the data manager 
(using a computer programme) and allocation done by a 
trial manager. To limit a socially desirable response set, 
a research assistant who was not involved in the recruit-
ment of the participants and is not working at the hospi-
tal conducted the follow-up assessment and was blinded 
to the treatment allocation.
Interventions
Treatment arm
The IDMI sessions included:
Session 1: A condensed form of motivational enhance-
ment therapy. Included aneEvaluation of why you want 
to quit using MA and monitoring your MA use. In this 
session, the client and the therapist worked together to 
explore the level of motivation to quit MA use and facili-
tated change talk by using elements from a motivational 
interviewing framework.
Session 2: Financial planning. In this session, the cli-
ent and therapist worked together to identify financial 
concerns (debt for example) associated with MA use and 
explored strategies to help improve the client’s financial 
situation.
Session 3: Behavioural intervention, prepara-
tion for MA use triggers. In this session, strategies 
to resist against MA use triggers were developed for 
implementation.
Session 4: Exposure therapy (via guided imagery). In 
this session, the therapist spent approximately 20 minutes 
asking the client to visualize and describe a typical day 
of MA use and all the senses, thoughts, emotions, and 
behaviours involved in MA use. At the peak of the client’s 
urge during the exposure (imagery), consequences of 
actions are introduced as well as coping mechanisms to 
help deal with these urges. This imagery process is writ-
ten as a script and audio recorded for the client to listen 
to at home.
Session 5: Impulsive beliefs: cognitive therapy. This ses-
sion involved the therapist and client working together to 
identify any thinking errors or erroneous beliefs that the 
client had which perpetuated his/her MA use. The goal 
was to learn how to develop healthy beliefs related to MA 
use.
Session 6: Relapse prevention. This session involved 
a review of all the skills and information learned 
throughout this programme. It focused on preparing the 
client for future triggers that will occur and which tempt 
him/her to engage in MA use. We did not formally evalu-
ate knowledge gained.
Session 7: Family involvement (optional). This session 
was optional and only completed at the client’s discre-
tion. It involved a discussion with the client and his/her 
family and the best role(s) all parties could play in the 
rehabilitation of the client.
Control arm
Participants randomized to the control arm were referred 
to a specialised, registered outpatient rehabilitation cen-
tre that was most convenient for them to attend. All out-
patient facilities provide a combination of motivational 
interviewing and cognitive behavioural-based counsel-
ling that incorporated both individual and group coun-
selling sessions.
Training and fidelity
Two clinical psychologists with more than 5 years’ expe-
rience delivering cognitive behavioural therapy were 
recruited and trained to deliver the intervention. The cli-
nicians received 3 full days of training in the treatment. 
Debriefing also occurred with the principal investigator 
as needed. To ensure intervention fidelity, all sessions 
were audio recorded and a random sample of 15 sessions 
from each psychologist was checked for fidelity using 
an intervention checklist that focused on intervention 
content. Both psychologists were highly adherent to the 
intervention, obtaining a fidelity rating of 91%.
Measures
The schedule of data collection is shown in Fig.  2 the 
SPIRIT Figure. Feasibility outcomes include: (1) feasibil-
ity of recruitment (numbers screened, number of eligible 
participants, number invited to participate, consent rates 
(for parents and adolescents), refusal rates and reasons 
for refusal; (2) appropriateness of data collected process 
and outcome measures (number of missing items and 
follow-up rates); (3) retention in the IDMI intervention 
(number of participants completed all sessions); (4) cli-
nician competency (scores on a competency checklists); 
(5) feasibility of randomisation and blinding (number of 
refusals to be randomised and field staff’s perceptions of 
contamination); (6) presence of adverse advents (number 
of study-related adverse events reported).
The performance of the primary outcome (frequency 
of MA use) was measured using the timeline follow-
back method (TLFB) [29]. Participants were instructed 
to indicate, on a printed calendar, which days in the past 
2 weeks they had used MA. Although this method was 
originally developed to measure the frequency of alcohol 
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Enrollment Allocation Post-enrollment 
TIMEPOINT** -t1 0 6 weeks 3 months 
ENROLLMENT: 
Pre-screen X    
Eligibility screen X    
Informed consent  X    
Allocation  X   
INTERVENTIONS: 




Age  X   





Employment and Relationship 
status 
X 
Primary outcome measures 
Alcohol Timeline Follow 
Back 
X X X 
Secondary outcome measures 
The Penn Alcohol Craving 
Scale 
X X X 
Clinical Global Impression 
(Severity) scale 
X X X 
Hamilton Rating Scale for 
Anxiety (HAM-A) 
Hamilton Rating Scale for 
Depression (HAM-D) 
X X X 
Sheehan Disability Scale 
(SDS) 
X X X 
Counsellor competencies 
Fig. 2 Standard Protocol Items: Recommendations for Clinical Trials (SPIRIT) Figure—schedule of data collection
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use, it has been shown to be a reliable and valid method 
to measure illicit drug use. Self-report amphetamine 
use using the TLFB has resulted in both high sensitiv-
ity (0.88) and specificity (0.96) compared to urine assay 
results [30]. The following secondary outcomes were also 
measured:
The Penn Alcohol Craving Scale (PACS) (modified for 
MA dependence) is a reliable and valid five-item self-
administered instrument for assessing craving for alco-
hol. Frequency, intensity, and duration of thoughts about 
MA use are assessed along with ability to resist use [31]. 
The PACS has shown excellent internal consistency 
(α = 0.92) and correlates with the Obsessive Compulsive 
Drinking Scale [32] and the Alcohol Urge Questionnaire 
[33]. The PACS has not been validated for illicit drug use. 
The internal consistency of the PACS in the current sam-
ple was 0.84.
Clinical Global Impression (Severity) scale (CGI) (Guy, 
1976) is a commonly used measure of symptom sever-
ity, treatment response and the efficacy of treatments 
in treatment studies of patients with mental disorders. 
Although the tools reliability and validity has not been 
assessed in a substance using population it has dem-
onstrated strong psychometric properties in different 
populations. For example, an investigation into the psy-
chometric properties of the CGI among people living 
with schizophrenia found that the reliability of CGI was 
high (intraclass correlation coefficient, ICC > 0.70) and 
the correlation coefficients between the CGI and the 
Global Assessment of Functioning was high (> 0.75) [34].
Hamilton Rating Scale for Depression (HAM-D) (Ham-
ilton, 1960) The HAM-D has been used internationally 
to assess the overall severity of depressive symptomatol-
ogy and has shown reasonable validity and reliability. For 
example, in a systematic review of 70 published studies 
that used the HAM-D and found adequate internal con-
sistency ranging from 0.46 to 0.97 and test-retest reliabil-
ity ranging from 0.81 to 0.98 [35].
Hamilton Rating Scale for Anxiety (HAM-A) (Ham-
ilton, 1959) The HAM-A was developed to measure the 
severity of anxiety symptoms. The scale consists of 14 
items, each defined by a series of symptoms, and meas-
ures both psychic anxiety (mental agitation and psycho-
logical distress) and somatic anxiety (physical complaints 
related to anxiety). The scale is often used in randomised 
controlled trials (RCTs) and has shown high interrater 
reliability (ICC = 0.74) and concurrent validity [36].
Sheehan Disability Scale (SDS) was developed to assess 
functional impairment in three inter-related domains; 
work/school, social and family life. Each of the 3 response 
items is scored on a 10-point Likert scale [37]. A study 
consisting of 1001 participants found that the SDS 
exhibited good reliability (Cronbach’s alpha = 0.89 and 
inter-item correlation between 0.70 and 0.79). Further, 
80% of the participants with a mental disorder showed 
elevated scores in this scale indicating reasonable validity 
[38].
Analysis
Descriptive statistics were used to report on all feasibility 
outcomes. To index the relative effects of the two treat-
ment conditions descriptive statistics were also generated 
for the overall sample and by treatment group. Baseline 
variables were tested for differences between those who 
completed the 3-month evaluation and those who did 
not using chi-square tests for categorical variables, or 
Fisher’s Exact where cell sizes were small, and t-tests for 
continuous variables, or Mann–Whitney–Wilcoxon tests 
if normality assumptions were not met. Linear mixed-
effects regression models with repeated measures were 
used to assess differences in outcome measures over 
time between groups, with fixed effects for baseline vari-
ables that were different between groups, time, treatment 
group, and treatment by time interaction, and random 
effects for participant. The regression coefficient of inter-
est is the treatment by time interaction. The primary 
regression analysis used an intention-to-treat approach 
with last observation carried forward (LOCF) to impute 
scores for missing data values. A secondary regression 
analysis only used data from those who completed the 
3-month follow-up (no imputation). All testing was two-
sided and a significance level of 0.05 was used through-
out. Analyses were conducted in SAS v9.4 (SAS Institute, 
Inc., Cary, NC) and R v3.2.2.
Results
A total of 278 individuals who use MA were pre-screened 
for possible study inclusion. From these patients, 200 
(72%) were excluded. Among those who were excluded, 
63 (31%) never arrived for their appointment, 30 (15%) 
did not have a grade nine education 7 (4%) had previ-
ously been diagnosed with a severe mental disorder. 
Twenty-three (11%) were receiving treatment elsewhere, 
33 (16%) had not used MA in the previous 2 weeks, 25 
(13%) reported that heroin was their drug of choice and 
19 (10%) were living with a partner who was using.
The remaining 78 participants were assessed for 
study eligibility in person, where a further 18 people 
were excluded as they had a severe mental illness and 
did not report MA as their drug of choice. All partici-
pants that were eligible consented to take part and were 
randomly allocated. The 60 eligible patients were then 
randomly allocated to either the intervention or con-
trol condition. There were no refusals and concerns 
from participants regarding randomisation and pro-
ject staff reported confidence in the randomisation and 
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blinding process, particularly as the follow-up assess-
ment was conducted by an individual who did not work 
at the hospital where the intervention sessions were 
being conducted. Recruitment for this feasibility trial 
took 9 months, approximately seven participants were 
recruited per month.
Table 1 shows the demographic characteristics of each 
group and the overall sample. There was an equal distri-
bution of men and women in the study. The average age 
of participants was 31  years old (SD = 6.5), with most 
people initiating MA use at 21  years of age (SD = 5.9). 
Most participants were single (n = 53; 88.3%) and unem-
ployed (n = 47; 78.3%). More Coloured participants 
(88.3%) participated in the intervention than Black (8.3%) 
or White (3.3%). These categories are not intended to 
reify sociocultural constructs, but rather to ensure that 
ongoing health disparities across groups can be explored.
Of the 30 participants who were randomised to the 
intervention group, 26 completed session one, 24 com-
pleted two sessions, 21 completed three sessions, 18 
completed four sessions, 15 completed five sessions and 
13 (43%) completed all six sessions. The reasons provided 
for treatment suspension included: imprisonment (n = 3), 
employment (n = 5) and loss of communication (n = 9). 
For the control group, 10 of the 30 participants attended 
at least one session at the outpatient facility, with a maxi-
mum of 3 sessions they were referred to. Three of the 
30 participants were admitted to an inpatient treatment 
centre.
In total, 39 (65%) participants completed the 6-week 
follow-up and 40 (67%) completed the 3-month follow-
up. Age at time of first use and age at baseline were the 
only variables that distinguished between participants 
who completed the 3-month follow-up and those who 
did not (age at first use: 22.3 years vs. 18.6 years, p = 0.04; 
age at baseline: 32.2 years vs. 28.6 years, p = 0.06). There 
were no significant differences between groups in terms 
of follow-up rates at 6-weeks and 3 months. See Table 2.
Improvements on all outcomes over time were 
observed for both the intervention group and the con-
trol group (see Table 3). In the intention-to-treat analy-
sis, the IDMI group displayed greater reductions in 
frequency of MA use (the primary outcome) than the 
control group. Results of the linear mixed-effects regres-
sion models revealed a statistically significant time by 
treatment group interaction (p = 0.01) at both 6 weeks 
(r = − 4.78, p < 0.01) and 3 months (r = − 4.63, p < 0.01) 
(Table 3). This finding was consistent when looking at the 
respondents who completed the 3-month follow-up only 
(p = 0.002) at 6 weeks (r = − 4.78, p < 0.01) and 3 months 
post-intervention (r = − 4.63, p < 0.01) (Table 4). Figure 3 
shows the average number of days using MA in the pre-
vious 2 weeks over time for the intention to treat (ITT) 
analysis with LOCF and the analysis with study com-
pleters only.
In addition, analysis of secondary measures demon-
strated a significant difference in the HAM-A score 
between the groups in the analysis that included 
Table 1  Baseline characteristics of participants, n = 60
Variable Total sample (n = 60) Control (n = 30) IDMI (n = 3 0) p-value
Age (mean, sd) 31.0 (6.5) 30.8 (6.7) 31.1 (6.4) 0.99
Gender (n, %)
 Male 32 (53.3) 13 (43.3) 19 (63.3) 0.12
 Female 28 (46.7) 17 (56.7) 11 (36.7)
Race (n, %)
 Black 5 (8.3) 4 (13.3) 1 (3.3) 0.51
 Coloured 53 (88.3) 25 (83.3) 28 (93.3)
 White 2 (3.3) 1 (3.3) 1 (3.3)
Relationship status (n, %)
 Single 53 (88.3) 27 (90.0) 26 (86.7) 0.99
  In relationship 7 (11.7) 3 (10.0) 4 (13.3)
Education (n, %)
 Did not finish high school 29 (48.3) 10 (33.3) 19 (63.3) 0.02*
 Finished high school 31 (51.7) 20 (66.7) 11 (36.7)
Employment (n, %)
 Unemployed 47 (78.3) 24 (80.0) 23 (76.7) 0.75
 Employed 13 (21.7) 6 (20.0) 7 (23.3)
Age at first use (mean, sd) 21.0 (5.9) 21.0 (6.0) 21.1 (5.8) 0.85
Received previous treatment (n, %) 28 (46.7) 12 (40.0) 16 (53.3) 0.30
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completers only (Table  4). The intervention group 
reported significantly lower scores on the HAM-A than 
the control group (p = 0.049) at both 6 weeks and at 3 
months post-intervention. There were no significant dif-
ferences between groups for the other secondary out-
come measures.
Discussion
This study is among the first to examine the feasibil-
ity of a brief treatment using imaginal desensitisation 
plus motivational interviewing for MA dependence in a 
low- and middle-income country context. Findings sug-
gest that although it is feasible to successfully identify 
and recruit participants to participate in an interven-
tion delivered by master’s level clinical psychologists, 
retention and follow-up rates could be improved. 
Although preliminary results indicate that this interven-
tion may be an efficacious intervention for reducing risk 
for MA, a number of modifications to the study design 
will need to be considered when progressing towards a 
future definitive randomised controlled trial. Findings 
indicate that it is feasible to identify and recruit individu-
als who use MA for such an intervention programme 
and that it is urgently needed among this population. Of 
the 278 MA users that contacted the research team, over 
half had never accessed substance use treatment services 
previously, and those who had were seeking treatment 
alternatives. In a recent systematic review investigat-
ing barriers for MA users to access treatment, the most 
common barriers highlighted were attitudinal in nature. 
Table 2  Means and standard deviations of groups at baseline, 6 weeks and 3 months follow-up
Variable Control (mean [sd]) IDMI (mean [sd])
Substance use (days in 2 weeks)
 Baseline 8.57 (4.29) 9.73 (3.95)
 6 week follow-up 6.43 (4.62) 4.83 (4.86)
 3 month follow-up 6. 90 (4.12) 4.80 (4.97)
Cravings (PENN craving)
 Baseline 22.50 (6.85) 20.37 (7.50)
 6 week follow-up 17.43 (8.35) 15.97 (7.61)
 3 month follow-up 13.13 (10.09) 14.83 (8.35)
Depression (HAM-D)
 Baseline 12.50 (5.25) 12.90 (6.22)
 6 week follow-up 11.23 (5.83) 10.20 (6.50)
 3 month follow-up 8.40 (5.37) 8.53 (6.69)
Anxiety (HAM-A)
 Baseline 20.27 (10.19) 18.70 (10.02)
 6 week follow-up 17.73 (10.08) 13.87 (9.27)
 3 month follow-up 14.63 (9.44) 8.79 (8.00)
Clinical Global Impressions Scale (CGI)
  Baseline 5.13 (0.97) 5.27 (0.91)
 6 week follow-up 4.57 (1.72) 4.03 (1.65)
  3 month follow-up 4.00 (1.89) 3.60 (1.81)
Sheehan disability (family)
 Baseline 8.40 (2.43) 7.77 (2.91)
 6 week follow-up 6.47 (4.02) 5.53 (3.69)
 3 month follow-up 4.50 (3.97) 4.43 (3.31)
Sheehan disability (work)
 Baseline 6.07 (3.85) 7.30 (2.49)
 6 week follow-up 4.70 (4.27) 5.50 (3.42)
 3 month follow-up 4.00 (3.80) 4.50 (3.75)
Sheehan disability (social life)
 Baseline 7.78 (2.27) 7.50 (2.86)
 6 week follow-up 5.53 (4.08) 4.70 (3.96)
 3 month follow-up 3.63 (3.93) 4.27 (3.63)
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Table 3 Intention to Treat Comparison of Groups on Primary and Secondary Outcomes
 Linear mixed-effects model; p-values entered in italic text; all other values are coefficients (standard error) unless otherwise stated
*p < 0.1; **p < 0.05; ***p < 0.01
Dependent variable





0.029 < 0.001 0.023 < 0.001 < 0.001 0.002 0.001 < 0.001






































type III SS 
p-value)
0.343 0.347 0.233 0.791 0.474 0.915 0.319 0.899
  Interven-
tion
1.104 (1.155) − 2.020 (2.131) 1.129 (0.937) −  0.242 
(0.909)
− 0.645 (0.894) 0.041 (0.387) − 2.302 (2.458) 0.230 (1.575)
Age at baseline 
(type III SS 
p-value)
0.337 0.279 0.106 0.072 0.156 0.093 0.497 0.499
− 0.070 (0.072) − 0.145 (0.133) − 0.089 (0.054) − 0.094* 
(0.051)
− 0.076 (0.053) − 0.038* 
(0.022)




0.197 0.185 0.826 0.449 0.466 N/A 0.006 0.002




in past 2 
weeks using 
methat base-
line (type III SS 
p-value)
N/A 0.651 0.191 0.774 0.992 0.013 0.381 0.496
0.107 (0.236) 0.128 (0.097) − 0.026 (0.091) − 0.001 (0.094) 0.091** (0.036) 0.602** (0.265) 0.129 (0.167)







0.013 0.169 0.786 0.386 0.672 0.283 0.312 0.529






0.667 (2.154) − 0.433 (1.063) − 0.567 (1.068) − 0.300 (0.985) − 0.667 (0.442) − 2.300 (1.997) − 1.433 (1.346)






3.833* (2.154) − 0.733 (1.063) 0.900 (1.068) 0.567 (0.985) − 0.533 (0.442) − 2.900 (1.997) − 0.267 (1.346)













Observations 180 180 180 180 180 180 180 180
Log Likelihood − 499.304 − 603.844 − 472.698 − 470.088 − 462.489 − 321.576 − 609.198 − 537.667
Akaike Inf. Crit. 1,018.608 1,229.687 967.396 962.175 946.978 663.153 1,238.396 1,095.333
Bayesian Inf. 
Crit.
1050.083 1264.245 1001.955 996.734 981.537 694.628 1269.870 1126.808
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Table 4 Comparison of groups on primary and secondary outcomes at 3-month follow-up: completers only
 Linear mixed-effects model; p-values entered in italic text; all other values are coefficients (standard error) unless otherwise stated
*p < 0.1; **p < 0.05; ***p < 0.01
Dependent variable





0.007 < 0.001 0.011 < 0.001 < 0.001 0.001 0.002 < 0.001






































type III SS 
p-value)
0.256 0.297 0.152 0.990 0.918 0.900 0.720 0.856









Age at baseline 
(type III SS 
p-value)
0.866 0.899 0.834 0.972 0.527 0.874 0.105 0.021










0.060 0.455 0.321 0.418 0.924 N/A 0.067 0.139






3.163* (1.671) 1.411 (0.932)
Number of 
days in past 2 
weeks using 
meth at base-
line (ttype III 
SS p-value)
N/A 0.991 0.173 0.050 0.138 0.009 0.564 0.925
− 0.003 (0.280) 0.167 (0.120) 0.201** (0.099) 0.188 (0.124) 0.107*** 
(0.039)
0.205 (0.353) − 0.019 (0.198)







0.002 0.230 0.531 0.753 0.948 0.171 0.049 0.660





















4.601* (2.661) − 1.628 
(1.453)






Constant 3.232 (3.134) 27.087*** 
(7.127)
7.266** (2.999) 7.905*** 
(2.466)





Observations 113 113 111 111 111 111 111 110
Log Likelihood − 297.348 − 367.367 − 289.208 − 280.067 − 285.397 − 196.906 − 369.688 − 320.790
Akaike Inf. Crit. 614.695 756.734 600.417 582.133 592.794 413.812 761.376 663.580
Bayesian Inf. 
Crit.
641.235 785.822 629.292 611.008 621.668 440.160 790.251 692.346
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These included the belief that treatment was not needed, 
stigma, a preference to be on their own to withdraw, and 
privacy and confidentiality issues [39]. Many of these bar-
riers may have been reduced in the present study where 
an individualized, brief treatment was provided outside 
of known specialist substance use treatment settings.
Nevertheless, keeping patients with a substance use 
disorder actively engaged in treatment posed many chal-
lenges. In this study, only 43% of participants in the inter-
vention arm completed all six sessions. Consistent with 
the data here, an evaluation of the implementation of the 
Matrix model at one clinic in the Western Cape found 
that over six years of the 2,233 clients who completed 
screening, approximately 44% (n = 986) initiated treat-
ment. Among those who initiated treatment, 45% com-
pleted at least four group sessions, 30% early recovery 
skills training (minimum eight group sessions), and 13% 
completed the full Matrix programme [22]. Other studies 
have also demonstrated high dropout rates from outpa-
tient services in this province, particularly in the first 2 
weeks of treatment [40].
Identifying methods to optimise treatment reten-
tion is crucial when considering the implementation 
of a definitive randomized control trial. To address this 
concern, we are considering using mobile technology to 
deliver the intervention. Given the availability of smart 
phones in this context, technology-assisted interven-
tions may provide a viable alternative to some of the 
face-to-face treatments [41]. In our experience, it is 
feasible to follow-up with substance using populations 
with much lower attrition rates should sufficient funds 
be available to track participants and conduct follow-
ups in the community [42].
Second, results from this feasibility trial provide guid-
ance on potentially useful outcome measures and pro-
vide some indications of preliminary effect sizes that 
could help sample size calculations for a larger, more 
definitive trial. Despite limitations, results also suggest 
that this intervention may be an efficacious intervention 
for reducing frequency of MA use. In this feasibility 
RCT, the intervention significantly reduced frequency 
of MA use in comparison to usual care. Participants in 
the intervention group reported significantly fewer days 
of MA use compared to the control group at both the 6 
week and 3-month follow-up assessments. These find-
ings are consistent with the available literature on the 
effectiveness of CBT-based approaches [14], where for 
example small to medium reductions are reported [43].
However, the intervention effect appears to diminish 
over time. This drop off is not surprising given evidence 
that after 90  day of treatment MA users are particu-
larly vulnerable for relapse. It has been argued that 
this period is associated with anhedonia that arises as 
neurotransmitter systems recover after extended peri-
ods of MA use [44]. Furthermore, other studies inves-
tigating the efficacy of psychosocial treatments for MA 
use also suggest that treatment effects decline over 
time [14, 45]. Given this evidence, additional efforts to 
improve the duration of the intervention effect, such as 
Fig. 3 Graph of average days of substance use over time by group
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additional intervention sessions, are warranted when 
considering a future definitive trial.
While our findings provide preliminary evidence that 
a six-session brief treatment holds promise for facilitat-
ing changes in MA use, in addition to efforts aimed at 
retention and intervention effect, further amendments 
to the study design will need to be considered when 
progressing towards a future definitive trial. First, par-
ticipants in the control condition received a referral 
to existing specialist outpatient facilities where vari-
ations in treatments and dosage were reported for the 
very limited number of participants who accessed any 
treatment. The lack of uniformity in the treatment pro-
vided to the control group could influence the inter-
nal validity of the study potentially compromising the 
results. Further consideration on the most appropri-
ate comparison group is essential when taking this to 
a definitive trial. Second, relying on self-reports of MA 
use as an outcome is problematic. Consideration must 
be given to the use of sophisticated biological mark-
ers of MA use (such as hair sample testing) that allow 
for assessments of the levels of MA use (and not just 
the presence or absence of metabolites) is warranted 
given the harm reduction rather than abstinence focus 
of the intervention. Third, grocery vouchers were given 
to participants at each assessment and treatment ses-
sion and transport costs to attend intervention sessions 
were covered. This could have potentially influenced 
participants motivation to participate in the study and 
could have contributed to the better retention rates in 
the intervention group (as the control group were not 
incentivised to attend treatment). Given that this type 
of incentive is unlikely to be provided in a real-world 
setting, it is recommended that these incentives are 
not provided in a definitive trial. Finally, this interven-
tion was delivered by master’s level psychologists, of 
which there are few in the public service. Future stud-
ies should explore whether this brief treatment could 
be task-shared to registered counsellors and commu-
nity health workers, given that it is both structured and 
manualised. In South Africa, there is a small but grow-
ing body of literature to show that with training and 
ongoing supervision, community health workers are 
able to deliver a range of evidence-based psychological 
treatments [46].
We also acknowledge that an intervention, such as 
the one described, cannot be considered a “solution” in 
isolation. It does not address the systemic issues within 
which substance use disorders arise, such as high lev-
els of unemployment and social inequality, which may 
have a maintaining effect on continued problematic 
use [47]. Adequately addressing problematic MA use 
requires intervention beyond the health care and social 
service sectors.
Conclusions
The results of the study suggest that it is feasible to suc-
cessfully identify and recruit participants to participate 
in a brief IDMI treatment for MA use delivered by mas-
ter’s level clinical psychologists. Our findings provide 
preliminary evidence that a six-session brief treatment 
holds promise for facilitating changes in MA use should 
concerns around retention and intervention effect be 
addressed. Findings provide evidence to support progres-
sion to a larger more definitive trial, pending proposed 
changes to the recruitment, intervention and retention 
protocols.
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